Zobrazeno 1 - 10
of 87
pro vyhledávání: '"35"'
Autor:
Martin J. Blaser, William V. Harford, W. L. Peterson, E. Lee, Guillermo I. Perez-Perez, C. Barnett
Publikováno v:
Gut. 47:467-472
BACKGROUND—Between 1976 and 1987, 35 cases of acute gastritis with hypochlorhydria (AGH) were seen in our research laboratory. The aims of this study were to determine the natural history of AGH and the role of Helicobacter pylori in its pathogenes
Autor:
Alfredo Alberti, A. Bertaggia, P. Cadrobbi, Flavia Bortolotti, C. Crivellaro, Giuseppe Realdi
Publikováno v:
Gut. 22(6)
Clinical, virological, and histological features of hepatitis B virus infection have been examined in 35 children, aged 1 to 11 years, known to be hepatitis B surface antigen (HBsAg) carriers for at least six months when entering the study. Only 10 p
Publikováno v:
Gut. 53:1117-1122
Background: Anti- Saccharomyces cerevisiae antibodies (ASCA) are a specific but only moderately sensitive diagnostic marker for Crohn’s disease. We sought to explore the role of ASCA as a prognostic marker for aggressive disease phenotype in Crohn
Publikováno v:
Gut. 31:926-929
We measured total plasma amino acid concentrations before and during pancreatic stimulation with secretin (1 clinical unit/kg/h) and caerulein (50 ng/kg/h) in 28 healthy volunteers, 60 patients with chronic pancreatitis (25 mild to moderate, 35 sever
Autor:
Hassan Alkharaan, Marco Del Chiaro, Zeeshan Ateeb, Carlos Fernández Moro, Margaret Chen, Katie Healy, Asif Halimi, Haleh Davanian, Luisa W. Hugerth, Roberto Valente, Liyan Lu, Rogier Aäron Gaiser
Publikováno v:
Gut. 68:2186-2194
ObjectivesIntraductal papillary mucinous neoplasms (IPMNs) are pancreatic cysts that can progress to invasive pancreatic cancer. Associations between oncogenesis and oral microbiome alterations have been reported. This study aims to investigate a pot
Autor:
Jorge Amil Dias, Baruch Yerushalmi, Dan Turner, Gigi Veereman Wauters, Athos Bousvaros, G Abitbol, Rotem Sigall Boneh, Mona Boaz, Eytan Wine, J. Kierkus, Malgorzata Sladek, Johanna C. Escher, Arie Levine, Michal Kori, Ron Shaoul
Publikováno v:
Gut, 68(2), 239-247. BMJ Publishing Group
ObjectiveCrohn’s disease (CD) pathogenesis associated with dysbiosis and presence of pathobionts in the lumen, intracellular compartments and epithelial biofilms. Azithromycin is active in all three compartments. Our goal was to evaluate if azithro
Autor:
Vigneswaran Kandasamy, Imran Aziz, David S Sanders, David G Partridge, Jack C Whiteley, Patricia Vergani, Jodie-Hannah Barnes, Mohammad Farhad Peerally, Simon S. Cross, Peter H.R. Green
Publikováno v:
Gut. 66:1563-1572
Background Seronegative villous atrophy (SNVA) is commonly attributed to coeliac disease (CD). However, there are other causes of SNVA. More recently angiotensin-2-receptor-blockers (A2RBs) have been reported as an association but data on SNVA have b
Publikováno v:
Gut. 23:382-389
In two groups of gallstone patients ideally suited for medical treatment, the effect of six to 18 months' therapy was compared retrospectively in 52 given chenodeoxycholic acid (CDCA) and 46 given ursodeoxycholic acid (UDCA). The minimum dose (mg kg-
Autor:
Steve Lewitzky, Wolfgang Hueber, Marc Vandemeulebroecke, Gervais Tougas, Bjoern Mellgard, Arthur P. Bertolino, Jacek Karczewski, Stephan Bek, Jan Wehkamp, Nicole Pezous, Brian G. Feagan, Gerard Bruin, Marco Londei, Simon Travis, Michael D Yao, Bruce E. Sands, Walter Reinisch, Peter D.R. Higgins, Claudia Berger, Marek Karczewski
Publikováno v:
Gut. 61:1693-1700
OBJECTIVE: The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. DESIGN: In a double-blind, randomised, placebo-controlled proof-of-concept study,
Autor:
Michael P. Manns, William Mullen, Jochen Wedemeyer, Jochen Metzger, Tobias J. Weismüller, Ahmed A. Negm, Tim O. Lankisch, Harald Mischak, Mohammed Dakna, Ruben R. Plentz, Tom H. Karlsen
Publikováno v:
Gut; Vol 62
Background Diagnosis and curative treatment of cholangiocarcinoma (CC) often comes too late due to the lack of reliable tumour markers especially in patients with primary sclerosing cholangitis (PSC). The authors recently introduced bile proteomic an